Silvia Maria B.
- Country
- France
- Department
- 2408: Hématologie et thérapie cellulaire
Research Overview
- Phase 3 Randomized Double‑Blind Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo + Ruxolitinib in JAK‑Inhibitor‑Naive Adults with Myelofibrosis
- Evaluation of Luspatercept and Epoetin Alfa in Low-Risk Myelodysplastic Syndromes Without Ring Sideroblasts Post-Erythropoiesis-Stimulating Agent Failure
- A Phase 3 Randomized Open-Label Study of Imetelstat Versus Best Available Therapy in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK-Inhibitors
Data & Insights
Has run more than one trial at 39 of 172 partner sites.
Specializations
Myelodysplastic Syndromes
This investigator specializes in treating low-risk myelodysplastic syndromes (MDS), particularly focusing on cases without ring sideroblasts. Their research interest extends to developing therapeutic approaches for patients who have not responded to or are ineligible for Erythroid Stimulating Agent (ESA) therapy.
- ESA-refractory MDS management
- Novel therapeutic combinations
- Treatment strategies for non-ring sideroblast MDS
Myelofibrosis Treatment
The investigator has significant expertise in treating intermediate-2 and high-risk myelofibrosis. Their work particularly focuses on developing treatment options for patients who have shown resistance to JAK-inhibitor therapy, exploring alternative therapeutic approaches for this challenging patient population.
- JAK-inhibitor resistant cases
- Advanced myelofibrosis management
- Novel therapeutic agents
Combination Therapy Development
This investigator works on advancing combination treatment approaches for myelofibrosis, with particular attention to novel therapeutic combinations. Their expertise includes evaluating the efficacy of combined targeted therapies in JAK-inhibitor naïve patients with myelofibrosis.
- Targeted therapy combinations
- First-line treatment optimization
- Treatment response assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.